Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases

Biogen and Ionis Expand Collaboration to Develop Therapy Candidates for Alzheimer’s, Other Neurological Diseases
Biogen and Ionis Pharmaceuticals are expanding their strategic collaboration through a new 10-year agreement to develop novel RNA-targeted therapy candidates for a broad range of neurological diseases, including Alzheimer’s disease. This agreement builds on the collaboration that produced Spinraza (nusinersen), the first and only approved treatment for spinal muscular dystrophy (SMA), and capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ experience in developing ribonucleic acid (RNA) targeted therapies through its antisense technology. The two companies will advance programs in disease areas including dementia, neuromuscular diseases, movement disorders, ophthalmology, neuropsychiatry, and others. Ionis will identify antisense therapy candidates while Biogen will lead non-clinical studies, clinical development, manufacturing, and commercialization. “Due to the ability of antisense oligonucleotides to directly intervene at the genetic origin of disease, we believe this approach could have a higher probability of success than traditional modalities, with a potentially more efficient development path to more rapidly help patients who suffer from diseases with limited or no treatment options," Michael Ehlers, MD, PhD, executive vice president of R&D at Biogen, said in a press release. "Our experience with antisense therape
Subscribe or to access all post and page content.

One comment

  1. Richard Fenn says:

    Are there any markers for the presence of the tau protein in the blood or in the cerebrospinal fluid?

Leave a Comment

Your email address will not be published. Required fields are marked *